Printer Friendly

FORMER CITICORP CHAIRMAN AND CEO WALTER WRISTON JOINS CYGNUS BOARD OF DIRECTORS

 FORMER CITICORP CHAIRMAN AND CEO WALTER WRISTON
 JOINS CYGNUS BOARD OF DIRECTORS
 REDWOOD CITY, Calif., July 16 /PRNewswire/ -- Walter B. Wriston, retired chairman and CEO of Citicorp, has been elected to the board of directors of Cygnus Therapeutic Systems (NASDAQ: CYGN), a company focused on transdermal drug delivery, the company announced today.
 "We are pleased to have an executive with Mr. Wriston's depth of experience joining us as we move forward to aggressively grow the company," said Dr. Gregory B. Lawless, Cygnus president and chief executive officer. "Mr. Wriston brings to Cygnus his unique perspective of business strategy through his extensive interaction with many of the world's most successful companies as well as through his knowledge of global financial markets."
 Wriston served for 17 years as CEO of Citicorp and its principal subsidiary, Citibank, N.A. He joined the bank in 1946 and served in the United States and overseas for 38 years. He became chairman in 1970.
 Graduated from Wesleyan University and the Fletcher School of Law and Diplomacy at Tufts University, Wriston is a trustee of the Manhattan Institute for Policy Research, a life governor of New York Hospital, and a member of the Board of Visitors of the Fletcher School of Law and Diplomacy.
 Wriston was chairman of President Reagan's Economic Policy Advisory Board, a member and former chairman of The Business Council, and a former co-chairman and policy committee member of The Business Roundtable. He is also the author of "Risk and Other Four-Letter Words," a collection of essays published by Harper & Row.
 Wriston is director of General Electric Co., Bechtel Investments Inc., Sequoia Ventures Inc., Tandem Computers Inc., United Meridian Corp., ICOS Corp., York International Corp., and BioResearch Laboratories Ltd.
 Cygnus is a leader and innovator in the development of advanced transdermal drug delivery systems and is in Redwood City. The Cygnus nicotine transdermal delivery system, Nicotrol(TM), was recently launched into the rapidly expanding nicotine patch market. The company has two other products in advanced clinical trials: an estradiol patch for the treatment of the symptoms of menopause and the prevention of osteoporosis; and a fentanyl patch for moderate to severe post-operative pain management. Cygnus Therapeutic Systems has 11 U.S. patents issued or allowed and over 300 patent applications worldwide covering its transdermal technology.
 -0- 7/16/92
 /CONTACT: Shirley Clayton of Cygnus, 415-599-3552/
 (CYGN) CO: Cygnus Therapeutic Systems ST: California IN: MTC SU: PER


RM-MC -- SF005 -- 9842 07/16/92 08:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:411
Previous Article:IWI DEBUTS COMMUNIQUE FAMILY OF PLUG & PLAY REMOTE ACCESS, BULLETIN BOARD SERVERS FOR NOVELL NETWORKS; INCLUDES WINDOWS 3.1
Next Article:SCHWAB REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
FRANK CARY, FORMER IBM CHAIRMAN AND CEO, JOINS CYGNUS BOARD OF DIRECTORS
'Tapping into the expertise.' (chief executive officers elected as corporate directors) (Welcome to the Board) (Column)
CYGNUS PROMOTES TWO OFFICERS; ROGER FRANCIS AND ALAN RUSSELL NAMED SENIOR VICE PRESIDENTS
Walter Wriston Joins PlusFunds.com Board Brings a Lifetime's Wealth of Financial Intellect and International Expertise to Groundbreaking Dot-Com.
Job one.
The first duty of a director: wisdom from Walter Wriston, a master banker and board leader.
Vion Mourns the Death of Director Walter B. Wriston.
Bits, bytes, and balance sheets; the new economic rules of engagement in a wireless world.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters